Stockscreener 앱 받기
119.70
1.22%
-1.4945
전일 마감가:
$121.19
열려 있는:
$121.07
하루 거래량:
2.49M
Relative Volume:
0.35
시가총액:
$148.48B
수익:
$29.05B
순이익/손실:
$8.11B
주가수익비율:
18.54
EPS:
6.4563
순현금흐름:
$9.16B
1주 성능:
-3.39%
1개월 성능:
+0.73%
6개월 성능:
+5.94%
1년 성능:
+32.14%
1일 변동 폭
$119.05
$122.25
1주일 범위
$119.05
$125.60
52주 변동 폭
$88.57
$128.70
길리어드 사이언스 Stock (GILD) Company Profile
명칭
Gilead Sciences Inc
전화
(650) 574-3000
주소
333 LAKESIDE DR, FOSTER CITY, CA
GILD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
119.68 | 150.36B | 29.05B | 8.11B | 9.16B | 6.4563 |
|
LLY
Lilly Eli Co
|
983.75 | 892.86B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
200.21 | 485.76B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
223.62 | 394.34B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
131.07 | 249.77B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
97.20 | 245.55B | 63.90B | 19.05B | 13.05B | 7.5596 |
길리어드 사이언스 Stock (GILD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-24 | 재개 | Truist | Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-08-19 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | 업그레이드 | Truist | Hold → Buy |
| 2025-07-25 | 업그레이드 | Needham | Hold → Buy |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-03-04 | 재확인 | Oppenheimer | Outperform |
| 2025-02-18 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-02-13 | 업그레이드 | DZ Bank | Hold → Buy |
| 2025-01-10 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-14 | 개시 | Citigroup | Buy |
| 2024-11-08 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2024-10-21 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-10-07 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 재확인 | Maxim Group | Buy |
| 2024-04-24 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2024-02-22 | 다운그레이드 | Truist | Buy → Hold |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-09-08 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-09-06 | 개시 | HSBC Securities | Reduce |
| 2023-07-24 | 재확인 | Barclays | Equal Weight |
| 2023-05-16 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 재개 | Piper Sandler | Overweight |
| 2023-01-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 재개 | BofA Securities | Neutral |
| 2022-12-09 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2022-10-31 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 재확인 | BMO Capital Markets | Market Perform |
| 2022-10-28 | 재확인 | Cowen | Outperform |
| 2022-10-28 | 재확인 | JP Morgan | Overweight |
| 2022-10-28 | 재확인 | Jefferies | Buy |
| 2022-10-28 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-10-28 | 업그레이드 | Truist | Hold → Buy |
| 2022-10-28 | 재확인 | Wells Fargo | Equal Weight |
| 2022-10-04 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-02-28 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 재확인 | BMO Capital Markets | Outperform |
| 2022-02-02 | 재확인 | BofA Securities | Neutral |
| 2022-02-02 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-02-02 | 재확인 | Truist | Hold |
| 2022-02-02 | 재확인 | Wells Fargo | Equal Weight |
| 2022-01-28 | 업그레이드 | Argus | Hold → Buy |
| 2022-01-06 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-12-06 | 개시 | Goldman | Neutral |
| 2021-11-19 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 재개 | Piper Sandler | Neutral |
| 2021-10-20 | 재개 | Cowen | Outperform |
| 2021-07-30 | 재확인 | BMO Capital Markets | Market Perform |
| 2021-07-30 | 재확인 | RBC Capital Mkts | Outperform |
| 2021-04-01 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | 업그레이드 | Redburn | Neutral → Buy |
| 2021-01-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-11-03 | 재개 | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-09-30 | 재개 | Jefferies | Buy |
| 2020-09-15 | 업그레이드 | Maxim Group | Hold → Buy |
| 2020-07-31 | 재확인 | Credit Suisse | Neutral |
| 2020-07-31 | 재확인 | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 재확인 | Piper Sandler | Overweight |
| 2020-07-31 | 재확인 | RBC Capital Mkts | Outperform |
| 2020-07-31 | 재확인 | SunTrust | Hold |
| 2020-07-31 | 재확인 | Wells Fargo | Equal Weight |
| 2020-07-20 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | 업그레이드 | SunTrust | Sell → Hold |
| 2020-05-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-05-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | 다운그레이드 | SunTrust | Hold → Sell |
| 2020-04-27 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-04-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | 다운그레이드 | CFRA | Hold → Sell |
모두보기
길리어드 사이언스 주식(GILD)의 최신 뉴스
Lombard Odier Asset Management Switzerland SA Raises Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Foundation Awards Over $3 Million to Support People Living With Metastatic Breast Cancer - Business Wire
Jump Financial LLC Takes Position in Gilead Sciences, Inc. $GILD - MarketBeat
Three Catalysts Driving Investor Attention Toward Gilead Sciences - AD HOC NEWS
Gilead Sciences, Inc. $GILD Shares Sold by Bank of Nova Scotia - MarketBeat
ASH25: CAR-T Leaders Gilead, J&J Show in Multiple Myeloma; Fulcrum Rises on Sickle Cell Data - BioSpace
WINTON GROUP Ltd Makes New Investment in Gilead Sciences, Inc. $GILD - MarketBeat
ASH: Gilead preps filing for anito-cel on iMMagine-1 data - pharmaphorum
What Does the Market Think About Gilead Sciences Inc? - Benzinga
Gilead Sciences, Inc. $GILD Shares Bought by Natixis - MarketBeat
35,296 Shares in Gilead Sciences, Inc. $GILD Bought by SVB Wealth LLC - MarketBeat
Gilead moves ahead on Chess Hatch project - San Mateo Daily Journal
L2 Asset Management LLC Buys 28,592 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
GILD's Yescarta Shows Promising Results for Lymphoma Patients - GuruFocus
GILD's Kite Unveils Promising CAR T-Cell Therapy Results at ASH Meeting - GuruFocus
ASH: Gilead’s Kite Plots 2026 Launch For Anito-Cel For Multiple Myeloma - Citeline News & Insights
ASH: Anito-cel strengthens best-in-class potential as Gilead's Kite preps for launch - Fierce Biotech
New data from Gilead, Arcellx multiple myeloma CAR-T suggest benefit over rival treatment - statnews.com
Federated Hermes Inc. Sells 1,885,664 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Position Decreased by Brown Advisory Inc. - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by Baird Financial Group Inc. - MarketBeat
Why The Narrative Around Gilead Sciences Is Shifting After HIV And Oncology Updates - Yahoo Finance
Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition - GlobeNewswire Inc.
First Trust Advisors LP Sells 1,512,069 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Arrowstreet Capital Limited Partnership Grows Position in Gilead Sciences, Inc. $GILD - MarketBeat
1832 Asset Management L.P. Makes New $4.69 Million Investment in Gilead Sciences, Inc. $GILD - MarketBeat
Marshall Wace LLP Grows Position in Gilead Sciences, Inc. $GILD - MarketBeat
Dodge & Cox Lowers Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Epoch Investment Partners Inc. Has $95.16 Million Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Bought by CW Advisors LLC - MarketBeat
Amundi Purchases 1,614,355 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Sprint Bioscience (Q3 review)Gilead deal a strong confirmation - marketscreener.com
Redeye: Sprint Bioscience (Q3 review)Gilead deal a strong confirmation - TradingView
Is Gilead Sciences Inc. (GIS) stock good for long term investingJuly 2025 Rallies & Stock Timing and Entry Methods - Newser
Gilead's Seat at the Table of Conversations Centered Around HIV - Gilead Sciences
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know - sharewise.com
VestGen Advisors LLC Lowers Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Channing Capital Management LLC Purchases 43,875 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Acquired by Guggenheim Capital LLC - MarketBeat
Groupe la Francaise Has $3.92 Million Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (GILD) Stock Outlook: Mizuho Lifts Target Amid Stronger Biktarvy Timeline - MSN
Gilead (GILD) Valuation After Fresh Buy Rating and Extended Biktarvy Exclusivity Boost Investor Confidence - Yahoo Finance UK
Gilead Sciences, Inc. $GILD Shares Bought by Loomis Sayles & Co. L P - MarketBeat
Invesco Ltd. Buys 3,394,330 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Jeffrey Bluestone Sells 5,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock - MarketBeat
Health Hires: Goodwin Partner Joins Incyte, Gilead GC Exits - Law360
Gilead Sciences (NASDAQ:GILD) CEO Sells $1,265,400.00 in Stock - MarketBeat
Gilead Sciences (NASDAQ:GILD) Director Sells $356,515.50 in Stock - MarketBeat
Gilead Sciences (NASDAQ:GILD) Director Sells $356,670.66 in Stock - MarketBeat
Transcript : Gilead Sciences, Inc. Presents at Citi Annual Global Healthcare Conference 2025, Dec-02-2025 11 - marketscreener.com
Insider Activity Update: Jeffrey Bluestone Executes Options Exercise, Resulting In $296K At Gilead Sciences - Benzinga
길리어드 사이언스 (GILD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
길리어드 사이언스 주식 (GILD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Bluestone Jeffrey | Director |
Nov 28 '25 |
Sale |
125.08 |
5,000 |
625,400 |
8,920 |
| Kramer Kelly A. | Director |
Nov 26 '25 |
Option Exercise |
81.00 |
2,806 |
227,286 |
4,145 |
| Kramer Kelly A. | Director |
Nov 28 '25 |
Option Exercise |
81.00 |
2,805 |
227,205 |
4,144 |
| Kramer Kelly A. | Director |
Nov 26 '25 |
Sale |
127.11 |
2,806 |
356,671 |
1,339 |
| Kramer Kelly A. | Director |
Nov 28 '25 |
Sale |
127.10 |
2,805 |
356,516 |
1,339 |
| O'Day Daniel Patrick | Chairman & CEO |
Nov 28 '25 |
Sale |
126.54 |
10,000 |
1,265,444 |
571,203 |
1.32%
자본화:
|
볼륨(24시간):